Wang X, Wang SS, Huang H, et al. - Among patients with early-stage triple-negative breast cancer, researchers investigated the effectiveness as well as the adverse impacts of low-dose capecitabine maintenance following standard adjuvant chemotherapy. In this randomized clinical trial, eligible patients were randomly assigned 1:1 to receive capecitabine (n = 222) at a dose of 650 mg/m² twice a day by mouth for 1 year without interruption or to observation (n = 221) following completion of standard adjuvant chemotherapy. Disease-free survival was assessed as the primary endpoint. Findings revealed that significantly improved 5-year disease-free survival was conferred by low-dose capecitabine maintenance therapy for 1 year vs observation in women with early-stage triple-negative breast cancer who underwent standard adjuvant treatment (82.8% vs 73.0%).